Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05968157 · ClinicalTrials.gov registry record · NA

MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick

A NA study of Breast Cancer, sponsored by University of Massachusetts, Worcester.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT05968157: Recruiting NA study of Breast Cancer, sponsored by University of Massachusetts, Worcester.

NCT05968157 is a NA study of Breast Cancer that is actively recruiting participants, run by University of Massachusetts, Worcester. The registered enrollment target is 200 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05968157, a NA study of Breast Cancer, is actively recruiting participants, sponsored by University of Massachusetts, Worcester.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

Accurate risk assessment is essential for the success of population screening programs and early detection efforts in breast cancer. Mirai is a new deep learning model based on full resolution mammograms. Mirai is a mammography-based deep learning model designed to predict risk at multiple timepoints, leverage potentially missing risk factor information, and produce predictions that are consistent across mammography machines. Mirai was trained on a large dataset from Massachusetts General Hospital (MGH) in the United States and found to be significantly more accurate than the Tyrer-Cuzick model, a current clinical standard. The primary aim of this study is to prospectively quantify the clinical benefit (i.e. MRI/CEM cancer detection rate) of Mirai-based guidelines and to compare them to the current standard of care. 1. Conduct a prospective study where patients who are identified as high risk by Mirai guidelines are invited to receive supplemental MRI within 12 months. 2. Compare cancer outcomes between patients only identified as high risk by Mirai and patients identified as high risk by existing guidelines The secondary aim is to study the impact of new guidelines by race and ethnicity, to ensure equitable improvements in cancer screening.

Primary Outcome

Cancer detection rate from breast MRI following Mirai assessment of high risk on a screening mammogram performed less than 1 year ago and compared with established CDR in traditional high risk screening.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Breast MRI
  • DEVICE MIRAI

Study Locations (1)

Massachusetts

  • UMass Medical School - Worcester

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-02-04
Est. Completion 2027-09
Phase NA

What NCT05968157 shows while recruiting

NCT05968157 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Breast MRI is the first listed.

NCT05968157 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05968157 about?

NCT05968157 is a clinical study titled "MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick". Accurate risk assessment is essential for the success of population screening programs and early detection efforts in breast cancer. Mirai is a new deep learning model based on full resolution mammograms. Mirai is a mammography-based deep learning model designed to predict risk at multiple timepoin...

What is the current status of trial NCT05968157?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-02-04. Estimated completion is 2027-09.

What conditions does trial NCT05968157 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05968157?

The interventions under investigation include: Breast MRI (DIAGNOSTIC_TEST), MIRAI (DEVICE).

Who is sponsoring clinical trial NCT05968157?

This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05968157 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05968157's enrollment target sits among peer trials

200 362nd of 1224 higher than 841 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05968157, the US trial registry maintained by the National Library of Medicine. NCT05968157 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.